What is HC Wainwright’s Estimate for PVLA Q4 Earnings?

Palvella Therapeutics (NASDAQ:PVLA) – HC Wainwright issued their Q4 2024 earnings estimates for Palvella Therapeutics in a note issued to investors on Thursday, December 26th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.39) for the quarter. HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.11) EPS, FY2025 earnings at ($3.93) EPS, FY2026 earnings at ($4.12) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($2.62) EPS.

Separately, Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Stock Up 0.7 %

Shares of NASDAQ:PVLA opened at $11.88 on Friday. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $22.32. The firm has a market cap of $15.68 million, a P/E ratio of -0.98 and a beta of 0.61.

Insider Activity

In other news, Director George M. Jenkins bought 4,000 shares of the stock in a transaction dated Wednesday, December 18th. The shares were acquired at an average price of $12.93 per share, with a total value of $51,720.00. Following the completion of the acquisition, the director now directly owns 180,671 shares in the company, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.39% of the company’s stock.